Compare Stocks: AGFY, SBTX, CRDL, and NERV

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGFY Agrify	$18.40 +1.2%	$21.79	$13.22 ▼ $48.84	$36.86M	9.96	31,892 shs	24,157 shs
CRDL Cardiol Therapeutics	$1.10 -4.3%	$1.75	$0.88 ▼ $2.34	$136.77M	0.88	1.66 million shs	631,701 shs
NERV Minerva Neurosciences	$2.35 -2.9%	$3.91	$2.28 ▼ $12.46	$115.55M	-0.1	154,740 shs	85,598 shs
SBTX Silverback Therapeutics	$4.07 +3.6%	$5.03	$2.80 ▼ $8.97	$146.76M	0.6	337,931 shs	2.22 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGFY Agrify	+1.21%	-5.74%	-14.12%	-17.19%	-59.81%
CRDL Cardiol Therapeutics	-4.35%	-10.57%	-42.11%	-9.09%	+1.85%
NERV Minerva Neurosciences	-2.89%	-26.10%	-32.47%	-44.96%	-6.37%
SBTX Silverback Therapeutics	+3.56%	-10.75%	-4.24%	-41.86%	-61.82%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGFY Agrify	$18.40 +1.2%	$21.79	$13.22 ▼ $48.84	$36.86M	9.96	31,892 shs	24,157 shs
CRDL Cardiol Therapeutics	$1.10 -4.3%	$1.75	$0.88 ▼ $2.34	$136.77M	0.88	1.66 million shs	631,701 shs
NERV Minerva Neurosciences	$2.35 -2.9%	$3.91	$2.28 ▼ $12.46	$115.55M	-0.1	154,740 shs	85,598 shs
SBTX Silverback Therapeutics	$4.07 +3.6%	$5.03	$2.80 ▼ $8.97	$146.76M	0.6	337,931 shs	2.22 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGFY Agrify	+1.21%	-5.74%	-14.12%	-17.19%	-59.81%
CRDL Cardiol Therapeutics	-4.35%	-10.57%	-42.11%	-9.09%	+1.85%
NERV Minerva Neurosciences	-2.89%	-26.10%	-32.47%	-44.96%	-6.37%
SBTX Silverback Therapeutics	+3.56%	-10.75%	-4.24%	-41.86%	-61.82%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGFY Agrify	0.00	N/A	N/A	N/A
CRDL Cardiol Therapeutics	2.50	Moderate Buy	$10.00	809.09% Upside
NERV Minerva Neurosciences	2.00	Hold	$10.33	339.72% Upside
SBTX Silverback Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest AGFY, SBTX, CRDL, and NERV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	NERV Minerva Neurosciences	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Strong Sell ➝ Hold
9/23/2026	CRDL Cardiol Therapeutics	HC Wainwright Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$9.00
9/21/2026	CRDL Cardiol Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
9/21/2026	NERV Minerva Neurosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
8/26/2026	CRDL Cardiol Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Buy	$11.00
8/17/2026	CRDL Cardiol Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Buy	$8.00 ➝ $10.00
8/14/2026	NERV Minerva Neurosciences	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold ➝ Mixed	$7.50 ➝ $10.00
8/12/2026	NERV Minerva Neurosciences	Zacks Research Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Hold ➝ Strong Sell

(Data available from 10/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGFY Agrify	$12.26M	3.01	N/A	N/A	$10.47 per share	1.76
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	$0.11 per share	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	($3.25) per share	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	$7.41 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGFY Agrify	-$41.75M	-$22.65	N/A	N/A	N/A	-424.11%	-185.90%	-72.67%	N/A
CRDL Cardiol Therapeutics	-$24.20M	-$0.25	N/A	N/A	N/A	N/A	-180.44%	-140.28%	11/12/2026 (Estimated)
NERV Minerva Neurosciences	-$293.42M	-$28.87	N/A	N/A	N/A	N/A	N/A	-31.72%	11/4/2026 (Estimated)
SBTX Silverback Therapeutics	-$89.48M	-$2.42	N/A	N/A	N/A	N/A	-29.62%	-28.20%	N/A

Latest AGFY, SBTX, CRDL, and NERV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/12/2026	Q3 2026	CRDL Cardiol Therapeutics	-$0.06	N/A	N/A	N/A	N/A	N/A
11/4/2026	Q3 2026	NERV Minerva Neurosciences	-$0.14	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	CRDL Cardiol Therapeutics	-$0.09	-$0.04	+$0.05	-$0.04	N/A	N/A
8/7/2026	Q2 2026	NERV Minerva Neurosciences	-$0.1933	-$0.14	+$0.0533	-$0.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGFY Agrify	N/A	N/A	N/A	N/A	N/A
CRDL Cardiol Therapeutics	N/A	N/A	N/A	N/A	N/A
NERV Minerva Neurosciences	N/A	N/A	N/A	N/A	N/A
SBTX Silverback Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGFY Agrify	1.43	2.64	2.52
CRDL Cardiol Therapeutics	N/A	5.55	5.55
NERV Minerva Neurosciences	N/A	20.15	20.14
SBTX Silverback Therapeutics	N/A	67.87	67.87

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGFY Agrify	5.98%
CRDL Cardiol Therapeutics	12.49%
NERV Minerva Neurosciences	34.56%
SBTX Silverback Therapeutics	74.89%

Insider Ownership

Company	Insider Ownership
AGFY Agrify	2.16%
CRDL Cardiol Therapeutics	5.25%
NERV Minerva Neurosciences	1.70%
SBTX Silverback Therapeutics	34.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGFY Agrify	140	2.00 million	1.96 million	Not Optionable
CRDL Cardiol Therapeutics	18	118.93 million	112.69 million	Not Optionable
NERV Minerva Neurosciences	7	47.75 million	46.94 million	Not Optionable
SBTX Silverback Therapeutics	83	36.06 million	23.65 million	Not Optionable

AGFY, SBTX, CRDL, and NERV Headlines

Recent News About These Companies

Meet the Silverback, the Leader of the Troop

October 17, 2024 | pbs.orgP

10 Fun Facts About Mountain Gorillas

September 18, 2024 | nationalgeographic.comN

CapstanTx secures $165 million to deliver precise in vivo cell engineering

July 28, 2024 | pharmaphorum.comP

ARS Pharmaceuticals Inc (SPRY)

May 11, 2023 | uk.investing.com

Wild Isles

March 12, 2023 | wwf.org.ukW

A look back at RNA Therapeutics – day one

February 23, 2023 | pharmaphorum.comP

SPRY ARS Pharmaceuticals, Inc.

January 24, 2023 | seekingalpha.com

ARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After Merger

November 22, 2022 | 247wallst.com

Dr. Sarina Tanimoto Discloses Position in SBTX / Silverback Therapeutics

November 18, 2022 | nasdaq.com

ARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxis

November 10, 2022 | finance.yahoo.com

ARS Pharmaceuticals Closes Merger with Silverback Therapeutics

November 8, 2022 | finance.yahoo.com

Silverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic Reactions

October 28, 2022 | markets.businessinsider.com

FDA accepts ARS Pharma’s NDA for Neffy

October 24, 2022 | thepharmaletter.comT

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERI

October 23, 2022 | kentuckytoday.comK

Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis

October 21, 2022 | finance.yahoo.com

Is Silverback Therapeutics Inc (SBTX) Stock a Good Investment?

October 19, 2022 | aaii.comA

SHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWN

October 12, 2022 | bakersfield.comB

INVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBT

September 17, 2022 | markets.businessinsider.com

SBTX Silverback Therapeutics, Inc.

September 15, 2022 | seekingalpha.com

SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBT

September 6, 2022 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGFY, SBTX, CRDL, and NERV Company Descriptions

Agrify NASDAQ:AGFY

$18.40 +0.22 (+1.21%)

As of 10/15/2026

Agrify Corporation offers hardware and software cultivation and extraction solutions for the cannabis and hemp industry in the United States. It offers vertical farming units and Agrify Insights Software-as-a-Service software; integrated grow racks and LED grow lights; and non-proprietary products designed, engineered, and manufactured by third parties, such as air cleaning systems and pesticide-free surface protection products. The company also provides associated services comprising consulting, engineering, and construction. In addition, the company offers hydrocarbon, alcohol, solventless, post-processing, and lab equipment, as well as provides indoor farming solutions. In addition, it offers equipment and services in a contract and purchase order. The company was formerly known as Agrinamics, Inc. and changed its name to Agrify Corporation in September 2019. Agrify Corporation was incorporated in 2016 and is headquartered in Troy, Michigan.

Cardiol Therapeutics NASDAQ:CRDL

$1.10 -0.05 (-4.35%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$1.12 +0.02 (+1.82%)

As of 10/16/2026 07:30 PM Eastern

Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.

Minerva Neurosciences NASDAQ:NERV

$2.35 -0.07 (-2.89%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$2.36 +0.01 (+0.43%)

As of 10/16/2026 07:30 PM Eastern

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.

Silverback Therapeutics NASDAQ:SBTX

$4.07 +0.14 (+3.56%)

As of 10/15/2026

Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AGFY, SBTX, CRDL, and NERV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AGFY, SBTX, CRDL, and NERV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AGFY, SBTX, CRDL, and NERV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGFY, SBTX, CRDL, and NERV Company Descriptions

Agrify NASDAQ:AGFY

Cardiol Therapeutics NASDAQ:CRDL

Minerva Neurosciences NASDAQ:NERV

Silverback Therapeutics NASDAQ:SBTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AGFY, SBTX, CRDL, and NERV Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AGFY, SBTX, CRDL, and NERV Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AGFY, SBTX, CRDL, and NERV Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGFY, SBTX, CRDL, and NERV Company Descriptions

Agrify NASDAQ:AGFY

Cardiol Therapeutics NASDAQ:CRDL

Minerva Neurosciences NASDAQ:NERV

Silverback Therapeutics NASDAQ:SBTX

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools